Unicycive Therapeutics (UNCY) Shares Outstanding (Weighted Average) (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $23.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 104.66% year-over-year to $23.9 million; the trailing twelve-month figure through Mar 2026 stood at $23.9 million (up 104.66% YoY), and the FY2025 full-year result was $15.9 million, up 137.17% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $23.9 million, up from $15.9 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $34.9 million in Q1 2024 and bottomed at $3.8 million in Q2 2024.
• The 5-year median for Shares Outstanding (Weighted Average) is $15.1 million (2022), against an average of $15.8 million.
• The widest annual swing landed in 2024, when Shares Outstanding (Weighted Average) plunged 75.11%; it then surged 234.09% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $15.1 million in 2022, then surged by 62.98% to $24.5 million in 2023, then tumbled by 72.7% to $6.7 million in 2024, then surged by 137.17% to $15.9 million in 2025, then jumped by 50.49% to $23.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $23.9 million (Q1 2026), $15.9 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.

Peer Comparison